Boulder Peptide Symposium – Oct 25-28
Billed as; the only conference focused solely on the pharmaceutical development of peptide therapeutics the symposium is being held in person again this year, and we will be there!
Unlocking the Therapeutic Potential of Complex GPCRs
Orion Biotechnology is a clinical stage company discovering and developing next-generation G Protein-Coupled Receptor (GPCR)-targeted therapeutics for the treatment of cancer and other serious diseases.
Orion’s novel drug modality involves precision engineering ligands of peptide and protein GPCRs to develop analogs with significant advantages over small molecule and antibody approaches
CCR5 Inhibitor Program
Orion’s lead compound, OB-002, is a GPCR analog of CCL5 with best-in-class potency and a proven mechanism of action shown to have broad applicability across a range of serious diseases, including Cancer, Infectious Disease and Neuroinflammatory disorders.
Recognized
Leadership
Previous
Next
Bio-Europe – Oct 25-28
The Bio-Europe Conference will be held virtually again this year, and Orion Biotechnology will be providing a pre-recorded presentation describing our exciting drug discovery technology for unlocking the therapeutic potential
LSX’s Inv€$tival Showcase – Nov 08-15
Orion will be presenting a video at the LSX’s Inv€$tival Showcase which is being held as a hybrid event with both online and in-person meetings. We are looking forward to
Orion Adds Industry Leader to Board
September 1, 2021
Ottawa, Canada, Aug. 31, 2021 (GLOBE NEWSWIRE) — Orion Biotechnology, a clinical stage company that is developing novel G Protein-Coupled Receptor (GPCR)-targeted therapeutics for the treatment of cancer and other
Orion Biotechnology Secures $11.5M Series A Financing
June 18, 2021
Ottawa, Canada [June 17, 2021]: Orion Biotechnology Canada Ltd., a clinical-stage biotechnology company, today announced that it has raised $11.5M USD in a Series A financing. The oversubscribed round was led
Orion Biotechnology Adds Four Experts to its Scientific Advisory Board
April 14, 2021
Ottawa, Canada, April 13, 2021 (GLOBE NEWSWIRE) — Orion Biotechnology Canada Ltd., a clinical stage biotechnology company focused on precision engineering small protein therapeutics, today announced the addition of four experts
Global Headquarters
343 Preston Street
11th floor,
Ottawa, On K1S 1N4
CANADA
+1 343.291.1032
Switzerland
Campus Biotech
Innovation Park
Avenue de Sécheron 15
1202 Genève
SWITZERLAND
Poland
Orion Biotechnology
Life Science Park
UI Bobrzyńskiego 14
30-348 Krakôw
POLAND
